How insulin therapy
should feel like
should feel like
Our most valuable asset is the difference we make in people's lives.
Life sciences should be about leveraging infrastructures as well as intellect.
Innovation is found in products, processes, people, and thinking.
Healthcare should be accessible, safe and empowering.
Anxiety should be removed at all cost from healthcare.
Albania, Andorra, Armenia, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Croatia, Cyprus, Czech Republic (Czechia), Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Jordan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Malaysia, Malta, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Romania, San Marino, Saudi Arabia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom.
The InsuJetTM community and medical professionals turn our scientific and medical discoveries into solutions for their life.
InsuJet™ has been in development for over two decades. We have been gathering clinical data and market feedback, for over a decade. At this stage we are confident that we are in a position to revolutionize the entire needle-free market.
2004 - Development of the technology starts in the UK.
2008 - Market approvel of the SQ-Pen. The first generation of the current family of needle-free inulin injection devices.
2009 - Global IP rights of technology acquired.
2010 - EU market approval.
2011 - InsuJet™ is covered by NHS.
2011 - Launch of the InsuJet™ V1.
2011 - 1st Clinical study
Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology.
Diabetes Care, August 2011
2012 - HK and China (CFDA) approval.
2013 - 2nd Clinical study into Needle-Free Jet Injection with Diabetes technology.
2014 - Australia (TGA) & New Zealand approval.
Launch of InsuJet™ V3.
New clinical studies validate and emphesize the effectiveness of InsuJet™ for patients of both type 1 and 2 diabetes.
InsuJet™ gets approval to sell in Malaysia.
InsuJet™ enters Middle East (KSA / JO)
Nugen MD acquires InsuJet™.
Canada HC approval.
Emergo appointed as UKRP.
InsuJet™ is signing new distributors in 10 new territories.
Used needles are a massive environmental concern. In the US alone, 7.8 bilion needles are disposed of on an annual basis, and most are for insulin use.
To fight this, we must push back on the use of single-use disposables. For every InsuJetTM user, we eliminate more than 1000 needles per year! That saves a lot of biohazardous waste and the added environmental cost of its collection.
In many countries where needles are not properly collected and disposed off. The elimination of single-use disposables helps to protect our environment.
Building innovative products requires working with world-class manufacturing partners and skilled employees. Our suppliers operate some of the most technologically advanced manufacturing facilities on the planet, designed to perform at the level of precision and quality necessary to build our products.
To maintain the highest level of conformity of our processes, we implement a Quality Management System that complies with ISO 13485:2016, which stipulates the requirments for medical device manufacturers and its suppliers to design, produce, store, distribute and dispose of medical devices. Our QMS is certified by our Notified Body, LNE/GMED, ID No. 0459. The InsuJetTM needle-free administration system is certified under MDD 93/42/EEC (until October 26, 2024), and currently under assessment of EU MDR 2017/745.
Our mission is to make the medical profession a safer place. Where needle-stick injuries are a thing of the past. Any needle-stick injury can cause emotional stress to healthcare workers as they are potentially exposed to dangerous patogents transmitting possible chronic and hazardous diseases. such as Hepetitus B, C and HIV.
Hospitals and clinics are required to provide safe medical devices to not only their patients, but to also their staff, to provide a safe and low risk work environment. Just like medical device manufacturers, they are the required to reduce risks to the lowest possible levels. This means that they need to provide safe alternatives to needles if available. NSI's with insulin delivery devices are the most common of all NSI's, and can be avoided with the InsuJetTM.
To ensure the device is safe to use, the device comes with an important safety feature, which is the counter-pressure release mechanism. This mechanism is designed to only release when it is pushed with the front of the device toward the target administation site. This prevents accidental firing, and makes the device more safe to use than other needle-free devices on the market without this feature.
We commit to continue improving the safety of needle-free technology by commiting to the best practices in Risk Management, Clinical Evaluation, Usability Engineering and Post Market Surveillance. We conduct Post Market Clinical Follow up studies to actively collect feedback on the clinical peformance of the devices in the market, so can continue to improve, making needle-free technology better and safer with every generation of devices.
The InsuJetTM team and its suppliers are held to the highest standards of labor and human rights, health and safety, environmental stewardship, and ethics.
We take care of our employees, who are critical to the success of the company, as they possess the know-how and understanding on how to design, manufacture and sell innovative medical devices according to the state of the art.
We take care of our distributors, who are our most important link to the end-users of the device. We rely on them to, not only make the device available, but to provide you with the best instructions possible to start using the InsuJetTM. We also rely on them to support you, and provide us with important feedback of how our devices are performing in ther market.
But maybe most importantly we try to take care of our end-customers, our early adopters and brand advocates, who are critical to not just our success, but to the success of needle-free technology in general.
Our worldwide corporate operations consider a sustainable approach. Not just reducing the use of (biohazardous) needles and its collection.
Sustainability is at the forefront of what we do. This is reflected by the clear choice for durability as opposed to the common medical industry trend of using single-use disposables.
The InsuJet needle-free injector is spring powered, which is more sustainable than gas powered alternatives that are on the market. The spring can be re-set by simply winding your device, so the energy needed for every injection is provided by you! This does not require any external tools, such as reset boxes, as is seen in competitor devices.
Our devices are build to last, and we warrant that our devices are free of defects under normal conditions of use or storage and within the indicated lifetime and expiration date.
01. Types d'insuline compatibles : humaine et animale ; Insulines à action rapide (bolus); analogues d'insuline à action rapide ; Insuline Humaine Régulière ; Insulines basales ; Action intermédiaire, généralement : NPH/ Isophane ; Action prolongée, couramment : Glargine, détémir, degludec ; Prémélanges (ex. 30/70).
02. Dans une enquête auprès des utilisateurs, 78 % des personnes interrogées ont répondu qu'elles recommanderaient InsuJet™ à d'autres.
03. Dans une enquête auprès des utilisateurs, 40 % des personnes interrogées ont répondu avoir remarqué qu'elles consommaient moins d'insuline.
04. L'injection par jet sans aiguille d'insuline à action rapide améliore le contrôle précoce de la glycémie postprandiale chez les patients atteints de diabète. Soins du diabète, octobre 2013.
05. Indice de masse corporelle et efficacité de l'injection par jet sans aiguille pour l'administration d'analogues d'insuline à action rapide, une analyse post hoc. Diabète, obésité et métabolisme, juillet 2012.
06. Amélioration du profil pharmacocinétique et pharmacodynamique de l'insuline à action rapide à l'aide de la technologie d'injection par jet sans aiguille. Soins du diabète, août 2011
07. Une étude pilote pour examiner la tolérance et la préférence de dispositif dans le diabète de type 1 de l'insuline séparée administrée par InsuJet™ par rapport à l'injection sous-cutanée. Technologie et thérapeutique du diabète, 2014.
08. Voir Medical Deck Cost Analysis - North America, 2022 disponible sur la page Partner.
09. Calculé à 4 injections par jour avec une aiguille hypodermique. 4 injections par jour, tous les jours de l'année, cela représente 1 460 aiguilles économisées par an.
*. L'InsuJet™ est calibré pour les insulines U-100
**. Le calibre d'aiguille 26-27 est couramment utilisé pour les injections sous-cutanées et mesure environ 0,40 à 0,45 mm de diamètre. L'orifice de la buse InsuJet™ mesure environ 0,15 mm de diamètre, ce qui est beaucoup plus petit que les calibres d'aiguille conventionnels utilisés pour les injections sous-cutanées d'insuline.
***. https://pubmed.ncbi.nlm.nih.gov PMID :18820853